PRIMARY MEMBRANOUS NEPHROPATHY

This study is testing an experimental drug called WAL0921 in people with specific kidney diseases that cause protein to leak into the urine. Participants will receive either the drug or a placebo via an IV infusion every two weeks for about three months. The main goals are to see…

This study is testing an experimental antibody called budoprutug in adults with primary membranous nephropathy, a rare autoimmune kidney disease. Researchers want to see if the treatment is safe and can help reduce kidney damage by targeting specific immune cells. About 45 partic…

This early-stage study is testing the safety and early effectiveness of a new cell therapy called NKX019 for people with active lupus nephritis or primary membranous nephropathy, two serious autoimmune kidney diseases. Participants will receive a one-time treatment cycle involvin…

This study is testing a new drug called povetacicept for people with primary membranous nephropathy, a serious autoimmune disease that damages the kidneys. Researchers will compare it to a standard treatment to see if it's better at putting the disease into remission. The goal is…

This study is testing an investigational drug called felzartamab for people with primary membranous nephropathy (PMN), an autoimmune disease that damages the kidneys' filters. The main goal is to see if felzartamab works better than the standard drug tacrolimus at reducing harmfu…

This study is testing if a newer drug called obinutuzumab works better than the current standard treatment for primary membranous nephropathy, a serious autoimmune kidney disease. It will involve about 144 adults whose disease is still active despite initial medication. The main …

This study is testing an investigational drug called ALXN1920 to see if it can reduce harmful protein loss in the urine of adults with primary membranous nephropathy, a serious autoimmune kidney disease. About 30 participants at high risk for their disease getting worse will rece…

This is the first human study to test the safety and early effects of a new drug called YK012 for primary membranous nephropathy, a kidney disease where the body's immune system attacks the kidneys. The trial will enroll 72 adults with this condition to find the safest dose and s…

This study is testing an investigational injection called SHR-2173 in adults with primary membranous nephropathy, a serious autoimmune kidney disease. The main goals are to see if the treatment is safe and if it helps patients achieve a positive response, which could mean reducin…